(34) E782-01

(19) Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) Publication number: **0 097 000**
A2

(12) EUROPEAN PATENT APPLICATION

(21) Application number: 83303168.5

(22) Date of filing: 02.06.83

(51) Int. Cl.³: **C 07 D 211/58**, C 07 D 405/12, A 61 K 31/445 // C07D213/64, C07D211/74, C07D319/20, C07C93/14, C07C121/66

(30) Priority: 10.06.82 GB 8216911
25.06.82 GB 8218407
15.03.83 GB 8307081

(43) Date of publication of application: 28.12.83 Bulletin 83/52

(84) Designated Contracting States: BE CH DE FR GB IT LI NL SE

(71) Applicant: **Beecham Wuelfing GmbH & Co KG, PO Box 25, D-404 Neuss (DE)**

(72) Inventor: **Maschler, Harald, Asternstrasse 1D, D-3204 Nordstemmen (DE)**

(74) Representative: **Stott, Michael John et al, European Patent Attorney Beecham Pharmaceuticals Great Burgh Yew Tree Bottom Road, Epsom Surrey KT18 5XQ (GB)**

(54) Amine derivatives.

(57) Compounds of the formula (I):



(I)

and pharmaceutically acceptable acid addition salts thereof, wherein,

Ar is optionally substituted phenyl or naphthyl, or pyridyl;

E is O, S or a bond;

R_5 is hydrogen, and

J is C_{3-6} polymethylene, optionally substituted by one or two groups selected from methyl or optionally derivatised hydroxy; or

Ar and R_5 together form a group



where Ar^1 is optionally substituted 1,2-phenylene;

Z is O or CH_2, and

m is 0 or 1, when E is O or S, or 1 when E is a bond;

R_1 is hydrogen, C_{1-4} alkyl or optionally substituted phenyl; C_{3-6} alkanoyl, or phenyl C_{2-6} alkanoyl, any phenyl moiety being optionally substituted; a group COR_2 where R_2 is C_{2-3} alkoxy, phenyl C_{1-4} alkoxy, the phenyl moiety being optionally substituted, or C_{1-4} alkoxy C_{2-4} alkoxy; or a group $CXNHR_3$ where X is O or S and R_3 is C_{2-4} alkyl, C_{2-4} alkenyl, phenyl or phenyl C_{1-4} alkyl, any phenyl moiety being optionally substituted; and R_4 is hydrogen or C_{1-4} alkyl, compositions containing them, and processes for their preparation.

EP 0 097 000 A2

C07D211/58

(19) Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) Publication number: **0 097 000**
A2

(12) **EUROPEAN PATENT APPLICATION**

(21) Application number: 83303168.5

(22) Date of filing: 02.06.83

(51) Int. Cl.³: **C 07 D 211/58**, C 07 D 405/12, A 61 K 31/445 // C07D213/64, C07D211/74, C07D319/20, C07C93/14, C07C121/66

No	références, formules, pages à photocopier, etc		No	classement
			(1)	C07D211/58
(2)	p. 25.	—	(2)	INF: C07D213/64A
(3)	p. 26, 27, 28, 29, 31	—	(3)	INF: C07D211/74
(4)	p. 30, 32, 33,	—	(4)	INF: C07D319/20
(5)	p 39, 40, 41	—	(5)	INF: C07D405/12 + 319 + 211
(6)	p 23	—	(6)	INF/concl/134D2C
7	p 24-25	—	7	INF/124BGSGSB2
8	p 15	—	8	INF/124BGSGSB3
				BERLIN
			(8)	C07C93/06
				233 03:83 3

0097000

B1271/B1280/
B1432

AMINE DERIVATIVES, COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THEIR PREPARATION

This invention relates to antiarrhythmic compounds, to pharmaceutical compositions containing them, and to processes for their preparation.

A class of compounds with antiarrythmic activity but minimal β-blocking effects on the heart or bronchioles has been found.

The present invention provides the compounds of the formula (I):



(I)

and pharmaceutically acceptable acid addition salts thereof,

wherein,

Ar is optionally substituted phenyl or naphthyl, or pyridyl;

E is O, S or a bond;
R_5 is hydrogen, and
J is C_{3-5} polymethylene, optionally substituted by one or two groups selected from methyl or optionally derivatised hydroxy; or
Ar and R_5 together form a group



where Ar^1 is optionally substituted 1,2-phenylene;

Z is O or CH_2, and
m is O or 1, when E is O or S, or 1 when E is a bond;
R_1 is hydrogen, C_{1-4} alkyl or optionally substituted phenyl; C_{3-8} alkanoyl, or phenyl C_{2-8} alkanoyl; any phenyl moietybeing optionally substituted; a group COR_2 where R_2 is C_{2-3} alkoxy, phenyl C_{1-4}alkoxy, the phenyl moiety being optionally substituted, or C_{1-4} alkoxy C_{3-4} alkoxy; or a group $CXNHR_3$ where X is O or S and R_3 is C_{2-4}alkyl, C_{2-4} alkenyl, phenyl or phenyl C_{1-4} alkyl, any phenyl moiety being optionally substituted; and R_4 is hydrogen or C_{1-4} alkyl.

When used herein 'optionally substituted' means optionally substituted by one or two substituents chosen from halogen, C_{1-4} alkyl, C_{1-4} alkoxy, C_{2-7} acyloxy, cyano or trifluoromethyl. When used herein

the term 'C_{2-7} acyloxy' is restricted to unsubstituted C_{1-6} hydrocarbylcarboxy.

Ar is preferably unsubstituted. When Ar is substituted as defined, suitable substituents include fluorine, chlorine, methyl, methoxy, cyano and trifluoromethyl. A preferred value of Ar is phenyl.

E may be O, S or a bond. Often E is O.

Ar^1 is preferably unsubstituted. When Ar^1 is substituted as defined, suitable substituents include fluorine, chlorine, methyl, methoxy, cyano and trifluoromethyl. A preferred value of Ar is 1,2-phenylene. E and Z are often each O and m is O or 1, preferably 1.

Suitable values of J include $CH.(CH_2)n$ with R_{10} attached to the CH, wherein n is 2 or 4 and R_{10} is hydrogen, methyl or hydroxy or derivatised hydroxy. n is preferably 2 or 3.

Derivatised hydroxy R_{10} include nitrato C_{1-4} alkoxy, in particular methoxy, phenyl C_{1-4} alkoxy; in particular benzyloxy, and C_{1-7} carboxylic acyloxy, such as C_{1-4} alkanoyloxy, in particular acetoxy. R_{10} is preferably hydroxy.

Examples of C_{1-4} alkyl for or within R_1 and R_{10} and for R_4 include methyl, ethyl, n- and iso-propyl and n-, and tert-butyl, often methyl, ethyl, n-propyl, or n-butyl. Favoured C_{1-4} alkyl include ethyl and n-propyl.

Examples of C_{2-4} alkenyl within R_1 include vinyl, allyl and E and Z prop-1-enyl.

Examples of C_{3-8} alkanoyl for or within R_1 include propionyl, n- and iso-butyryl,2,2-dimethylpropanoyl (pivaloyl) and n-valeryl, preferably n-butyryl and n-valeryl. Examples of C_{2-8} alkanoyl in R_1 optionally substituted phenyl C_{2-8} alkanoyl include the above examples of C_{3-8} alkanoyl and acetyl. Examples of C_{1-4} alkanoyl for R_{10} include appropriate of the foregoing and acetyl.

Optionally subsituted phenyl within R_1 is often unsubstituted.

Examples of C_{1-4} alkoxy within R_1 include methoxy, ethoxy and n- and iso-propoxy.

From the foregoing it will be appreciated that suitable R_1 groups include methyl, ethyl and n-propyl; optionally substituted phenyl; propionyl, n and iso-butyryl and 2,2-dimethylpropanoyl (pivaloyl) ethoxycarbonyl, n- and iso-propoxycarbonyl, optionally substituted benzyloxycarbonyl and phenylpropoxycarbonyl; 3-methoxypropoxycarbonyl, ethylcarbamoyl, n- and iso-propylcarbamoyl, n- and tert-butylcarbamoyl, vinylcarbamoyl, allylcarbamoyl, E- and Z- prop-2-enylcarbamoyl, optionally substituted phenylcarbamoyl, optionally substituted benzylcarbamoyl, and phenethylcarbamoyl; ethylthiocarbamoyl, n- and iso-propylthiocarbamoyl, n- and tert-butylthiocarbamoyl, phenylthiocarbamoyl, benzylthiocarbamoyl, vinyl-thiocarbamoyl, allylthiocarbamoyl and E- and Z- prop-2-enylthiocarbamoyl.

A value of R_1 of interest is n-butylcarbamoyl. Favoured R_1 include n-butyryl, n-valeryl, ethoxycarbonyl, n-propoxycarbonyl, n- propylcarbamoyl

isopropylcarbamoyl and n-propylaminothiocarbonyl, in particular n-propylcarbamoyl.

The compounds of the formula (I) may contain an optical centre e.g.at the point of substitution by an R_{10} optionally derivatised hydroxyl group or a methyl group. The compounds may thus be provided in R-form, S-form or in mixtures thereof such as the RS-form. The RS-form is particularly apt in view of its greater ease of synthesis. The invention extends to all isomers including enantiomers of the compounds of all formula (I) and to mixtures thereof including racemates.

It is preferred that the compounds of formula (I) are in substantially pure form.

The compounds of the formula (I) may also form solvates and the invention extends to such solvates.

The compounds of the formula (I) may form acid addition salts at the NR_4 nitrogen atom, and at the NR_1 nitrogen atom when it is a non-amidic nitrogen atom.

The pharmaceutically acceptable salts of the compounds of the formula (I) include acid addition salts with conventional acids such as hydrochloric, hydrobromic, phosphoric, sulphuric, citric, tartaric, lactic and acetic acids.

The salts of the compounds of the formula (I) also include quaternary ammonium salts. Examples of such salts include such compounds quaternised by compounds

such as R_7 - Y wherein R_7 is C_{1-6} alkyl, phenyl - C_{1-6} alkyl or C_{5-7} cycloalkyl, and Y is an anion of an acid. Suitable examples of R_7 include methyl, ethyl and n- and iso-propyl; and benzyl and phenylethyl. Suitable examples of Y include the halides such as chloride, bromide and iodide.

Crystalline acid addition salts are favoured in view of their enhanced stability. Crystalline salts may be solvated, for example hydrated.

A group of compounds of formula (I) is of formula (IA):



(IA)

and pharmaceutically acceptable acid addition salts thereof,

wherein

Ar^2 is optionally substituted phenyl or naphthyl, or pyridyl;
R_1 is C_{1-4} alkyl or optionally substituted phenyl; C_{3-6} alkanoyl, benzoyl or phenyl C_{2-6} alkanoyl, any phenyl moiety being optionally substituted, a group COR_2 where R_2 is C_{2-3} alkoxy, phenyl C_{1-4} alkoxy, the phenyl moiety being optionally substituted, or C_{1-4} alkoxy C_{3-4} alkoxy; or a group $CXNHR_3$ where X is O or S and R_3 is C_{1-4} alkyl, C_{2-4} alkenyl, phenyl or phenyl C_{1-4} alkyl, any phenyl moiety being optionally substituted; and R_4 is hydrogen or C_{1-4} alkyl.

A second group of compounds of formula (I) is of formula (IB):



(IIB)

and pharmaceutically acceptable acid addition salts thereof,

wherein

Ar^1 is optionally substituted 1, 2-phenylene;

Z is O or CH_2;

m is O or 1;

R_{11} is a group where R_1 is C_{1-4} alkyl or optionally subsituted phenyl; C_{3-6} alkanoyl, or phenyl C_{2-6} alkanoyl, any phenyl moiety being optionally substituted; a group COR_2 where R_2 is C_{1-4} alkoxy, phenyl C_{1-4} alkoxy, the phenyl moiety being optionally substituted, or C_{1-4} alkoxy C_{3-4} alkoxy; or a group $CXNHR_3$ where X is O or S and R_3 is C_{2-4} alkyl, C_{2-4} alkenyl, phenyl or phenyl C_{1-4} alkyl, any phenyl moiety being optionally substituted; and R_4 is hydrogen or C_{1-4} alkyl.

Another group of compounds within formula (I) is of formula (II):



(II)

wherein

Ar^2 is optionally substituted phenyl or naphthyl or pyridyl;

R^1_1 is C_{3-8} alkanoyl or optionally substituted phenyl C_{2-8} alkanoyl; and

E, J, R_4 and R_5 are as defined in formula (I).

Suitable, favoured and preferred variables are as so described for corresponding variables under formula (I).

A further group of compounds within formula (I) is of formula (III):



(III)

wherein the variables are as defined in formulae (I) and (II).

Suitable, favoured and preferred variables are as so described for corresponding variables under formula (I).

Another group of compounds within formula (I) is of formula (IV):



(IV)

wherein

R^2_1 is a group COR_2 where R_2 is C_{2-3} alkoxy, phenyl C_{1-} alkoxy, the phenyl moiety being optionally substituted,

or C_{1-4} alkoxy C_{3-4} alkoxy; or a group $CXNHR_3$ where X is O or S and R_3 is C_{2-4} alkyl, C_{2-4} alkenyl, phenyl or phenyl C_{1-4} alkyl, any phenyl moiety being optionally substituted; and the remaining variables are as defined in formula (II).

Suitable, favoured and preferred variables are as so described for corresponding variables under formula (I).

A further group of compounds within formula (I) is of formula (V):



(V)

wherein the variables are as defined in formulae (I) and (IV).

Suitable, favoured and preferred variables are as so described for corresponding variables under formula (I).

A group of compounds of interest is of formula (VI):



(VI)

wherein:
n and R_1 are as defined in formula (I); and R_6 is hydrogen, C_{1-4} alkyl, C_{1-4} alkoxy, C_{2-7} acyloxy, cyano or trifluoromethyl.

Suitable and favoured and preferred R_1 and R_6 are so described under formula (I).

A group of compounds within formula (VI) is formula (VII):



(VII)

wherein

n is 2, 3 or 4; and
R_1^3 is C_{3-8} alkanoyl, C_{2-3} alkoxycarbonyl, or $CXNHR^1_3$ where X is O or S, and R^1_3 is C_{3-4} alkyl.

Suitable, favoured and preferred R^3_1 are as so described for corresponding variables under formula (I).

A second group of compounds within formula (VII) is of formula (VIII):



(VIII)

wherein R^1_3 is as defined in formula (VII), and n^1 is 2 or 3.

n^1 is preferably 3

$R^1{}_3$ is preferably n-propyl.

The present invention also provides a process for the preparation of a compound of the formula (II) whch process comprises the reaction of the compounds of the formulae (IX) and (X):

(IX)

(X)

wherein

R_9 is R_1 as defined or benzyl optionally substituted in the phenyl ring;

i) a) L is CHR_5JNH_2 and X and Y together are oxo;

b) L is $CH_2R_5J^1CHO$ or $CH_2R_5J^2COCH_3$ where J^1 is C_{2-4} polymethylene optionally substituted by one or two groups selected from methyl or optionally derivatised or protected hydroxy, and J^2 is C_{2-4} polymethylene optionally substituted by a methyl or optionally derivatised or protected hydroxy group, X is NH_2 and Y is H;

ii) a) L is $CHR_5\ J^3\ Q_1$ or $CHR_5J^1COQ_2$ where J^3 is J with any hydroxy group protected and Q_1 and Q_2 each are a group readily displaceable by a nucleophile. X is NHR_4 and Y is H;

b) L is $CHR_5J^3NHR_4$, X is Q_1 and Y is H; or

c) E is O or S, L is H or an alkali metal atom, X is $Q_2CHR_5-J^2-NR_4$ where Q_3 is a group readily displaceable by a nucelophile and Y is H;

iii) a) L is CHR_5J^4CHO or $CHR_5J^5COCH_3$ where J^4 is a bond or C_{1-2} polymethylene optionally substituted by a methyl or protected or derivatised hydroxy group and J^5 is a bond or C_{1-2} polymethylene, Y is H and X^1 is $M_1J^6NR_{12}$ where J^6 is C_{1-3} polymethylene determined by J^4 or J^5 and optionally substituted by a methyl or derivatised hydroxy group when J^4 is unsubstituted, M_1 is a lithium (I) or halomagnesium (II) group and R_{12} is an N-protecting group; or

b) L is $CHR_5J^4M_1$ or $CHR_5J^5CHM^1.CH_3$, Y is H and X is $CHO.J^6NR_{12}$;

iv) a) L is $CHR_5.J^6$  wherein J^6 is C_{1-3} polymethylene optionally substituted by a methyl or protected or derivatised hydroxy group, Y is H and X is NHR_4;

or

b) E is O or S, L is H or an alkali metal atom, Y is H and X is  J^6NR_4; or

v) ArEL is  where Z and E are each

independantly O or S and L_1 and L_2 are each H or an alkali metal atom, Y is H and X is $Q_1(CH_2)mCH.JNR_4$ wherein Q_4 and Q_5 are each

Q_5

independently a group readily displaceable by a nucleophile;

and thereafter as necessary reducing the resulting compound, or in the resulting compound converting R_9 benzyl to R_1, deprotecting any protected hydroxy group, converting R_{12} to hydrogen, optionally converting R_1 or R_4 to other R_1 or R_4 and optionally salifying the resultant compound of formula (I).

Suitable examples of Q_1, Q_3 Q_4 and Q_5 include halide such as Cl, or I or labile acyloxy groups such as OSO_2CH_3 and $OSO_2.C_6.H_4.p\text{-}CH_3$. Suitable examples of Q_2 include halide such as Cl or Br, acyloxy such as C_{1-4} alkanoyloxy, and hydroxy.

Suitable examples of L alkali metal atoms include soidum and potassium.

It will be appreciated by the skilled man that a protected hydroxyl group is a conventional group readily convertible after a desired reaction to a hydroxyl group. An R_{12} N-protecting group is a conventional group similarly readily removable.

Examples of protected hydroxyl include C_{1-4} alkoxy and C_{2-7} acyloxy as defined and described in and under formula (I), benzyloxy optionally substituted in the phenyl ring by one or two substituents selected from C_{1-4} alkyl, C_{1-4} alkoxy, trifluoromethyl, halogen or nitro; and tetrahydropyranyloxy.

Examples of R_{12} N-protecting groups include benzyl optionally substituted as for benzyl above.

In process variant i), the condensation of the compounds of the formulae (IX) and (X) is conveniently effected at non-extreme temperatures at about ambient, in a dry inert polar solvent, such as dry methanol.

When the condensation eliminates water, i.e. X and Y are oxo, it is preferably to carry out the reaction in the presence of a dehydrating agent, for example molecular sieves.

The use of a non-aqeous acid catalyst can be advantageous, for example hydrogen chloride or p-toluenesulphonic acid, or alternatively an acid addition salt of the compound of formulae (IX) or (X) containing the amino function.

The product compound must be reduced to give a compound of formula (I). This is conveniently effected in situ, and most conveniently simultaneously with the condensation.

The reduction of the product compound is conveniently simultaneously effected with a mild reducing agent, such as a mild inorganic complex hydride, for example sodium cyanoborohydride.

If a mild inorganic complex hydride reductant is used, the reaction is generally carried out in a dry, inert polar solvent, such as dry ethanol, maintained at neutral or acid pH, for example pH5-7 with for example hydrogen chloride with less than 7.

Non-extreme temperatures at about ambient are generally suitable.

Alternatively, the reduction may be effected sequentially, optionally with isolation of the condensation product and conventional transition -

metal catalysed hydrogenation may be employed, using for example palladium - or platinum - charcoal, at atmospheric pressure or a slight excess thereover. The above solvents and temperatures are apt.

In variants ii) and v), reaction is generally effected in an inert solvent, at a non extreme temperature, for example solvent reflux temperature. The presence of an acid acceptor, such as potassium carbonate or an appropriate organic base is often advantageous.

When L is $CHR_5J^1COQ_2$, Q_2 may be hydroxyl, when reaction may be effected in the presence of a dehydrating agent such as dicyclohexylcarbodiimide.

Subsequent reduction of the carbonyl function may be effected by using a strong reductant such as lithium aluminium hydride.

Alternatively, the reduction may be carried out concomitantly by effecting reductive alkylation for example using $L=CHR_5J^1COOH$ in the presence of an inorganic hydride reductant such as sodium borohydride.

In variant ii) c) reaction is generally effected in the presence of a strong base which, if L is H, often convertes it in situ to an alkali metal atom.

In variant iii), where M is a magnesium (II) halide group, the compound of formula (IX) or X may be prepared in situ under conventional conditions for Grignard reagents. Those are: reaction of the halide, preferably the bromide, corresponding to the compound of formula (IX) or (X) with a molar equivalent or excess of dry, grease-free magnesium particles in a dry ether, for example THF, dimethoxyethane or diethyl ether, free of protic solvents. THF is a preferred

solvent. The presence of trace quantities of dibromoethane may be advantageous. Ambient and non-extreme depressed temperatures are suitable, for example between ambient and -15°C, although gentle initiative heating may be advantageous.

When M is lithium, the compound of formula (IX) or (X) may be prepared in situ under conventional indirect metallation conditions, for example by reaction of the above corresponding halide, preferably the bromide with n-butyl lithium. Temperatures of ambient to -60°C are suitable. The completed reaction is conveniently quenched with water.

In variant iv) reaction is normally carried out in an inert solvent, for example an ether such as diethyl or diisopropyl ether at solvent reflux temperature. The reaction proceeds well in the presence of a strong inorganic base, such as sodium amide.

As regards the subsequent reaction steps:

When protected hydroxy is of the form $R_{13}O$ where R_{13} is C_{1-4} alkyl, conversion is conveniently effected by conventional methods, such as by boron tribromide or boron triiodide or iodotrimethylsilane. Warm aqueous hydrobromic acid or pyridine hydrochloric may also be used.

When R_{13} is C_{2-6} alkanoyl or benzoyl optionally substituted as defined deprotection may be effected convnetionally, for example by acidic or basic hydrolysis.

When R_{13} is optionally substituted benzyl as defined above, or tetrahydropranyl, conversion is conveniently effected by conventional methods such as transition metal catalysed hydrogenolysis, using for

example palladium or platinum-charcoal, at about atmospheric pressure. Non-extreme temperatures at about ambient are generally suitable.

Hydroxy and derivatised hydroxy may be interconverted by conventional etherification deetherification, esterification and deesterification reactions, as appropriate.

When R_{12} is optionally substituted benzyl as defined, conversion to hydrogen may be carried out conventionally, for example by hydrogenolysis. Suitable reaction conditions are as so described for R_{10} hydrogenolysis.

R_1 groups will not generally be interconverted but those which correspond to R_{12} groups as defined may be removed as described for R_{12}, and the resulting amine function conventionally acylated, alkylated reductively alkylated or treated with a corresponding iso(thio)cyanate to introduce R_1.

R_1 groups will generally be interconverted in the precursor intermediates to the compounds of formula (X).

Suitable alkylating or acylating agents in both cases will have the form R_1Q_2 where Q_2 is a group readily displaceable by a nucelophile.

Suitable Q_2 when R_1 is alkyl are as noted above for Q and Q_1.

When R_1 is acyl, suitable Q_2 include halo, hydroxy and C_{1-4} alkoxy, in particular halo.

Reaction is normally effected, when R_1 is C_{1-4} alkyl, as for N-alkylation in the main process.

When R_1 is acyl, reaction is usually effected without solvent if both reagents are liquid at room temperature, or otherwise in an inert solvent such as toluene or diethyl ether, usually at room temperature. As noted for main-process acylation, the presence of an acid acceptor, especially when Q_2 is halo is preferred.

When R_1 is of the formula $CXNHR_3$ as defined acylation is generally effected using the corresponding iso(thio)cyanate $XCN.R_3$, under conventional conditions for urethane formation.

R_4 hydrogen is conveniently converted to R_4 C_{1-4} alkyl by reductive alkylation, for example by reaction of the compound of the formula (I) with the corresponding C_{1-4} alkanoic acid in the presence of an inroganic hydride reductant such as sodium borohydride.

Conversion to R_4 methyl may be effected with formaldehyde in the presence of a mild reductant such as sodium cyanoborohydride in an inert highly polar solvent such as acetonitrile.

It will, of course, be appreciated that all the foregoing conversions may also be effected on corresponding variables in corresponding intermediates which are not of formula (I), as appropriate under any given reaction conditions.

From the aforegoing it will be appreciated that this invention also provides a second process for the preparation of a compound of the formula (I) or a pharmaceutically acceptable salt thereof, which process comprises the de-protection of a compound of the formula (XI).



(XI)

wherein J^7 is J or J in which any hydroxyl function is protected; R_8 is R_4 as defined or an N-protecting group; and R_9 is as defined with the proviso that at least one of J^7, R_8 and R_9 contains protected hydroxyl or is an N-protecting group respectively, and therafter, as necessary in the resultant compound converting R_1 or R_4 to other R_1 or R_4, and optionally salifying the resultant compound of formula (I).

Suitable process conditions are as so described for the relevant first process steps hereinbefore.

The invention also provides a process for the preparation of a compound of the formula (I), which process comprises the reduction of a compound of the formula (XII):



(XII)

in tautomerism with the form of formula (XIII)



(XIII)

wherein G is the trivalent analogue of J, and the remaining variables are as defined in formula (I).

Suitable process conditions are as so described for the relevant first process steps hereinbefore.

The acid addition salts of compounds of formula (I) may be prepared in entirely conventional manner by reacting a compound of the formula (I) in base form with the chosen acid.

The quaternary ammonium salts of the compounds of the formula (I) may be prepared in conventional manner for such salts, such as by reaction of the chosen compound of the formula (I) with a compound R_7Y as defined. This reaction is suitable carried out in an appropriate solvent such as acetone, methanol, ethanol, dimethylformamide and the like, at ambient or raised temperature and pressure.

The invention also provides a pharmaceutical composition comprising a compound of the formula (I), or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier.

Such compositions may be adapted for oral or parenteral administration, and as such may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconsitutable powders, injectable and infusable solutions or suspensions the compositions may also be in the form of suppositories. Normally, orally administrable compositions are preferred.

Tablets and capsules for oral administration may be in unit dose presentation form, and may contain conventional excipients such as binding agents, fillers, tabletting lubricants, disintegrants, and

acceptable wetting agents and the like. The tablets may be coated according to methods well known in normal pharmaceutical practice. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs or may be presented in a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (whcih may include edible oils), preservatives, and if desired conventional flavouring or colouring agents, and the like.

For parenteral administration, fluid unit dosage forms are prepared utilizing the compound of the formula (I) and a sterile vehcile. The compound, depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions the compound can be dissolved for injection and filter sterilized before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, preservatives and buffering agents can be dissolved in the vehicle.

Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilized by exposure to ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.

As is common practice, the compositions will usually be accompanied by written or printed directions for use in the medical treatment concerned.

It will of course be realised that the precise dosage used in the treatment of any of the hereinbefore described disorders will depend on the actual compound of the formula (I) used, and also on other factors such as the seriousness of the disorder being treated.

The invention provides a compound of formula (I) for the treatment or prophylaxis of cardiac arrhythmias.

The invention further provides a method of treatment or prophylaxis of cardiac arrythmias in mammals including humans comprising the administration to the sufferer of an effective amount of a compound of the formula (I) or a pharmaceutically acceptable salt thereof. The "effective amount" will depend in the usual way on a number of factors such as the nature and severity of the malady to be treated, the weight of the sufferer, and the actual compound used.

However, by way of illustration, unit doses will suitably contain 0.01 to 20 mg of the compound of formula (I), for example 0.02 to 10 mg, usually 5 to 10 mg.

The following Examples illustrate the preparation of compounds of formula (I), and the following Descriptions illustrate the preparation of intermediates thereof.

Satisfactory ^1H n.m.r. data were obtained for all the following products.

Description 1

4-phenoxy-3-hydroxyvaleronitrile (D.1)



Acetonitrile (48g) was added with stirring to a suspension of $NaNH_2$ (105g) in dry diethyl ether (1.7l) over 0.5 hr, and the suspension was refluxed for a further 0.5 hr.

1- phenoxy - 2,3 - epoxypropane (180g) was added, and the suspension was refluxed for 6 hr. with stirring under nitrogen. The mixture was cooled to room temperature and the yellow-brown precipitate was filtered off under suction, washed with diethyl ether (x4) and added to a stirred ice-diethyl ether mixture. The resulting ethereal solution of the precipitate was separated, and the aqueous phase further extracted with diethyl ether (x3).

The combined ether extracts were extracted with M HCl washed to neutral with water, dried (Na_2SO_4), filtered and the solvent was removed in vacuo,

yielding (D.1) (132g, 58%) as a pale yellow oil which crystallised in the refridgerator, used subsequently without further purification.

Analysis:

	C	H	N	O
calc. for $C_{11}H_{13}NO_2$	69.09	6.85	7.32	16.73
found	69.06	6.83	7.31	16.68

Description 2

5-phenoxypentan-4-ol-1-amine (D.2)



(D.2)

Nitrile (D.1) (132g) in diethyl ether (600 ml) was added dropwise at 0°C with vigorous stirring under nitrogen to $LiAlH_4$ (41g) suspended in dry diethyl ether (1.8l). The mixture was then stirred for 2.5 hr. at room temperature and then refluxed for 20 min.

Excess $LiAlH_4$ was destroyed by dropwise addition of water. The ethereal phase was separated off, and the aqueous layer was extracted with diethyl ether. The combined ethereal extracts were dried (Na_2SO_4), filtered, and the solvent was removed in vacuo.

The oily residue was dissolved in M HCl, basified (M NaOH) to pH 11, and the solution extracted with diethyl ether (x 3).

and at pH13 with dichloromethane (x 3).
The combined organic extracts were dried (Na_2SO_4) filtered and the solvent was removed in vacuo yielding (D.2) (86 g, 70%) as a colourless oil, crystallising on standing in the refrigerator.

m.pt. 39-40°C

Analysis

	C	H	N	O
calc. for $C_{11}H_{17}NO_2$	67.66	8.78	7.17	16.39
	67.51	8.75	7.19	16.24

The following are prepared analogously:



No.	R
(D3)	4 - AcO
(D4)	4 - Cl
(D5)	4 - Me



No.	R
(D6)	H
(D7)	4 - Me
(D8)	4 - Me O.



(D9)

Description 3

Piperid - 4 - one (D.10) (unstable)



(D.10)

Piperid-4-one hydrate hydrochloride(200g) in water (800ml) was neutralised with NaOH (47g) in water (200ml), and the solution extracted with chloroform (x4). The organic layer was dried (Na_2SO_4), filtered and used in solution.

Description 4

1 - Ethoxycarbonylpiperid-4-one (D11.)



(D11)

(D10) (10g), ethyl chloroformate (12g) and K_2CO_3 (14g) were stirred together at room temperature for 40 hr under nitrogen.

The mixture was filtered, and filtrate solvent was removed in vacuo. The residue was treated with diethyl ether, filtered and the ether removed in vacuo yielding (D11.) (12.4g, 76%)as a pale yellow oil used without further purification.

The following were prepared analogously:



No.	A
(D12)	CO-OPr^n
(D13)	CO.O-CH_2Ph
(D14)	CO Et
(D15)	CO Pr^n
(D16)	CO Bu^n

The following are prepared analogously:

No.	
(D17)	CO.O$(CH_2)_2$- 
(D18)	COPr^i
(D19)	CO- 
(D20)	CO CH_2- 
(D21)	CO $(CH_2)_2$- 
(D22)	Pr^n
(D23)	Ph
(D24)	
(D25)	CO_2Pr^i
(D26)	Me
(D33)	$CO_2(CH_2)_3$OMe

Description 5

1 - Propylaminocarbonylpiperid-4-one (D.31)



(D31)

To piperid-4-one (11.8g) was added n-propyl isocyanate in small portions at room temperature with stirring. After stirring 48hr the solvent was removed in vacuo, and the residue was treated with diethyl ether, yielding (D.31) (19.1g, 86%) as a pale yellow oil.

The following were prepared analogously:



No.	A
(D28)	$CONH\ Bu^n$
(D29)	CO NH Ph
(D30)	CONHEt
(D31)	$CONHPr^i$
(D32)	$CSNHPr^n$

The following are prepared analogously:

No.	A
(D34)	CO NH Bu^t
(D35)	CO NH. CH: CH_2
(D36)	CO NH. CH: $CH.CH_3$
(D37)	CO NH 
(D38)	CO NH CH_2 Ph
(D39)	CO NH $(CH_2)_2$- 
(D40)	CS NH Et
(D41)	CS NH Pr^n
(D42)	CS NH Pr^i
(D43)	CS NH Bu^n
(D44)	CS NH Bu^t
(D45)	CS NH Ph
(D46)	CS NH CH_2Ph
(D47)	CS NH.CH: CH_2
(D48)	CS NH. CH_2CH: CH_2
(D49)	CO_n-C_5H_{11}
(D50)	CO_n-C_6H_{13}
(D51)	CO_n-C_7H_{15}

Description 6

4-[2-(2,3-dihydrobenzo-1,4-dioxinyl)]-4-hydroxy-butyronitrile

(D52)



(D52)

Disodium catechol was reacted with 3,4-dichloro-1,2-expoxybutane by the method of US Patent No. 4212808, to give 2-(1,2-expoxyethyl)-2,3-dihydrobenzo-1,4-dioxin.

Acetonitrile (52g) was added with stirring to a suspendion of $NaNH_2$ (23 g) in dry diethyl ether (350 ml) over 0.5 hr, and the suspension was refluxed for a further 0.5 hr.

2-(1,2-epoxyethyl)-2,3-dihydrobenzo-1,4-dioxin, (25 g) was added, and the suspension was refluxed for 6 hr. with stirring under nitrogen. The mixture was cooled to room temperature and the yellow-brown precipitate was filtered off under suction, washed with diethyl ether (x4) and added to a stirred ice-diethyl ether mixture.

Description 7

The following are prepared analogously to Description 4.



No.	A
(D53)	
(D54)	$COCH_2Ph$
(D55)	$COOCH_2Ph$

Description 8

4-[2-(2,3-dihydrobenzo-1,4-dioxinyl)]-4-hydroxybutylamine (D56)



$CHOH\ (CH_2)_3NH_2$ (D56)

Nitrile (D.1) (15 g) in diethyl ether (100 ml) was added dropwise at 0°C with vigorous stirring under nitrogen to $LiAlH_4$ (4.8 g) suspended in dry diethyl ether (200 ml). The mixture was then stirred for 2.5 hr at room temperature and then refluxed for 20 min.

Excess $LiAlH_4$ was destroyed by dropwise addition of water. The ethereal phase was separated off, and the aqueous layer was extracted with diethyl ether. The combined ethereal extracts were dried (Na_2SO_4), filtered, and the solvent was removed in vacuo.

The oily residue was dissolved in M HCl, basified (M NaOH) to pH 11, and the solution extracted with diethyl ether (x 3) and at pH13 with dichloromethane (x 3). The combined organic extracts were dried (Na_2SO_4) filtered and the solvent was removed in vacuo to minimum solution volume.

The solution was eluted down a silica gel column (chloroform methanol, 3:1) yielding (1) (8 g, 51%) as an oil crystallising on standing in the refrigerator.

Analysis

	C	H	N	O
calc. for $C_{12}H_{17}NO_3$	64.55	7.67	6.30	21.49
found:	64.30	7.49	6.70	21.45

The following are prepared analoguously:



No.	R
(D57)	6-Et
(D58)	6-Cl
(D59)	6-Me

Example 1

4-(5-phenoxy- 4' hydroxypentylamino)-1-ethoxycarbonyl-pipe.idine



(14)

(D.2) (27g) was dissolved in dry methanol (110ml), and the solution neutralised to pH7 by adding ethanolic HCl solution and cooled to room temperature. After adding 1-ethoxycarbonylpiperid-4-one (44g), $NaCNBH_3$ (6g) was added to the mixture under cooling and stiring, under nitrogen. After 0.5hr, 3Å molecular sieves were added and the mixture stirred at room temperature for 16hr.

The resulting precipitate was filtered off under suction, washed with methanol, and the filtrate solvent was removed in vacuo.

The oily residue was extracted with diethyl ether at pH 7, and the aqueous layer at pH 14, was extracted twice with chloroform and washed with water.

After drying (Na_2SO_4) the extract was filtered and evaporated to dryness in vacuo crystallisation from diethyl ether yielded (1) (31g, 70%) as colourless crystals.

m. pt. 86-88°C.

Analysis

Calc.	for $C_{19}H_{23}N_2O_4$	65.12	8.63	7.99	18.26
found		65.08	8.66	7.95	18.25

The compounds of Table 1A and Table 1B were prepared analogously.

The compounds of Tables 2,3 and 4 are prepared analogously.

Table 1A



No.	A	n	% increase of voltage electro stimulation test dose 32mg/kg i.d., 6 guinea pigs.
1	$-C(=O)-C_2H_5$	3	47,7*
2	$-C(=O)-C_3H_7n$	3	50,8*
3	$COBu^n$	3	83*
4	$-C(=O)-NH-C_2H_5$	3	18,5*
5	$-C(=O)-NH-C_3H_7n$	3	77,8*†
6	$CONHPr^i$	3	58*
7	$CSNHPr^n$	3	109*
8	$CONHPr^n$	2	80,9*†
9	$CONHPr^n$	4	75*
10	$CONHPr^i$	2	28*

† 30 mg/kg i.d.

Table 1A (contd)



No.	A		% increase of voltage electro stimulation test dose 32mg/kg i.d., 6 guinea pigs.
11	$-\overset{O}{\overset{\|}{C}}-NH-C_9H_9^n$	3	66.7* (8mg/kg)
12	$-\overset{O}{\overset{\|}{C}}-NH-$ 	3	-
13	$-CH_3$	3	18,8*
14	$-\overset{O}{\overset{\|}{C}}-OCH_2-CH_3$	3	56,1*
15	$-\overset{O}{\overset{\|}{C}}-O-CH_2CH_2-CH_3$	3	-
16	$-C\overset{O}{\underset{O-CH_2}{=}}$ 	3	25,4*

Table 1B



No	A	% increase of voltage electro stimulation test dose 32mg/kg i.d. 6 guinea pigs.
17	CO_2Et	23 *

Table 1C



No.	E	A	m	% increase of voltage electro stimulation test dose 32mg/kg i.d. 6 guinea pigs
18	-	$CONHPr^n$	4	12.1*
19	O	CO_2Et	5	29.4*
20	O	$CONHPr^n$	5	29*
21	O	$CSNHPr^n$	5	11*
53	-	$CONHPr^n$	3	33*

Table 2



No.	R	A	No.	R	A
22	H	Pr^n	38	H	CONH-  OMe
13	H	Ph	39	H	CONH CH_2Ph
14	H		40	H	$CONH(CH_2)_2$-  OAC
15	H	$COPr^i$	31	H	CSNHEt
16	H	CO- 			
17	H	$COCH_2$  F	32	H	$CSNHPr^i$
18	H	$CO(CH_2)_2$-F	33	H	CSNH Bu^n
29	4-AcO	COOEt	34	H	CSNH Bu^t
30	H	$COOPr^i$	35	H	CSNHPh
21	H	$COO(CH_2)_2$  Me	36	H	$CSNHCH_2Ph$
22	H	$COO(CH_2)_3OMe$	37	H	CSNH.CH CH_2
23	H	CONH Bu^t	38	H	$CSNH.CH.CHCH_3$
24	H	$CONHCH:CH_2$	49	H	$CO.n\text{-}C_5H_{11}$
25	H	$CONHCH:CH.CH_3$	50	H	$CO.n\text{-}C_6H_{13}$
26	4-Cl	$CONHPr^n$	41	H	$CO.n\text{-}C_7H_{15}$
37	4-Me	CONH Bu^n	52	H	CONHEt

Example 2

4-[4'-[2-(2,3-dihydrobenzo-1,4-dioxinyl]-4'hydroxybutylamino]-1-ethoxycarbonylpiperdine (54)



(54)

(27 g) was dissolved in dry methanol (110 ml), and the solution neutralised to pH7 by adding ethanolic HCl solution and cooled to room temperature. After adding 1-ethoxycarbonylpiperid-4-one (44 g), $NaCNBH_3$ (6 g) was added to the mixture under cooling and stiring, under nitrogen. After 0.5 hr, 3 Å molecular sieves were added and the mixture stirred at room temperature for 16 hr.

The resulting precipitate was filtered off under suction, washed with methanol, and the filtrate solvent was removed in vacuo.

The oily residue was extracted with diethyl ether at pH 7, and the aqueous layer at pH 14 was extracted twice with chloroform and washed with water.

After drying (Na_2SO_4) the extract was filtered and evaporated to dryness in vacuo crystallisation from diethyl ether yielded (54).

m.pt. 83°C (ether)

Analysis		C	H	N	O
Calc.	for $C_{20}H_{30}N_2O_5$	63.47	8.00	7.47	21.13
found		63.54	8.06	7.50	21.15

Compound (55) of Table 3 was prepared analogously
The compounds of Table 4 are prepared analogously.

Table 3



No.	A	% increase of voltage electro. stimulation test dose 32 mg/kg i.d, 6 guinea pigs.
(54)		39.4
(55).		10.8 (16mg/kg)

Table 4



No.	R	A	No.	R	A
56	H	Me	77	6-Cl	$CONHPr^n$
57	H	Pr^n	78	6-M3	$CONHBu^n$
58	H	Ph	79	H	CONHEt
59	H		80	H	$CONHPr^i$
60	H	COMe	81	H	$CONHBu^n$
61	H	COEt	82	H	$CONHBu^t$
62	H	$COPr^n$	83	H	$CONH.CH:CH_2$
63	H	$COPr^i$	84	H	$CONH.CH:CH.CH_3$
64	H		85	H	CONHPh
			86	H	
65	H	$COCH_2Ph$	87	H	$CONHCH_2Ph$
66	H		88	H	
67	H		39	H	CSNHEt
68	H	COOMe	90	H	$CSNHPr^n$
69	6-EtO	COOEt	91	H	$CSNHPr^i$
70	H	$COOPr^n$	92	H	$CSNHBu^n$
71	H	$COOPr^i$	93	H	$CSNHBu^t$
72	H	$COOBu^n$	94	H	$CSNHCH_2Ph$
73	H	$COOCH_2Ph$	95	H	$CSNHCH_2Ph$
74	H		96	H	$CSNH.CH:CH_2$
75	H	$COO(CH_2)_2OMe$	97	H	$CSNH.CH_2CH:CH_2$
76	H	$COO(CH_2)_3OMe$	98	H	$CSNH.CH:CHCH_3$

Pharmacology of Compounds

Test Procedure to Demonstrate Antiarrythmic Effects

Electrostimulation Test

Method 1

According to the method by SZEKERES, L. and PAPP, G.J., (Naunyn-Schmiedebergs Arch. exp. Path. Pharmak. 245, 70 (1963), arrhythmias are induced in Guinea pigs by electostimulation of the right ventricle of the heart. The animals are anesthetized with Urethane (1.2 g/kg i.p.) and artificially respired before a needle electrode is inserted in the right ventricle of the heart. Substances are given intraduodenally 30 min before the stimulation. The voltage needed for induction of extrasystoles in control animals (n=6) is compared with that required for induction of arrhythmias in treated animals (n=6). The difference is statistically evaluated by the unpaired t-test (STUDENT)

Method 2

Arrhythmias are elicited by serial electrical shocks (50HZ impulse duration; 0.5mins) applied to the right-ventricle of guinea pig via needle electrodes. The therapeutic effects of test compounds are determined by infusing these compounds in the jugular vein at a solution concentration of 3 mg/ml and an infusion speed of 0,55 ml/min.

The results on compounds tested are shown in Table 1.

Toxicity

No compound-induced toxic effects were observed in the above tests.

Claims

1. A compound of formula (I):



(I)

or a pharmaceutically acceptable salt thereof,

wherein,

Ar is optionally substituted phenyl or naphthyl, or pyridyl;

E is O, S or a bond;
R_5 is hydrogen, and
J is C_{3-5} polymethylene, optionally substituted by one or two groups selected from methyl or optionally derivatised hydroxy; or
Ar and R_5 together form a group



where Ar^1 is optionally substituted 1,2-phenylene;

Z is O or CH_2, and
m is O or 1, when E is O or S, or 1 when E is a bond;
R_1 is hydrogen, C_{1-4} alkyl or optionally substituted phenyl; C_{3-8} alkanoyl, or phenyl C_{2-8} alkanoyl, any phenyl moietybeing optionally substituted; a group COR_2 where R_2 is C_{2-3} alkoxy, phenyl C_{1-4}alkoxy, the phenyl moiety being optionally substituted, or C_{1-4} alkoxy C_{3-4} alkoxy; or a group $CXNHR_3$ where X is O or S and R_3 is C_{2-4}alkyl, C_{2-4} alkenyl, phenyl or phenyl C_{1-4} alkyl, any phenyl moiety being optionally substituted; and R_4 is hydrogen or C_{1-4} alkyl.

2. A compound according to claim 1 of formula (IA):



(IA)

wherein

Ar^2 is optionally substituted phenyl or naphthyl, or pyridyl;
R_1 is C_{1-4} alkyl or optionally substituted phenyl; C_{3-6} alkanoyl, benzoyl or phenyl C_{2-6} alkanoyl, any phenyl moiety being optionally substituted, a group COR_2 where R_2 is C_{2-3} alkoxy, phenyl C_{1-4} alkoxy, the phenyl moiety being optionally substituted, or C_{1-4} alkoxy C_{3-4} alkoxy; or a group $CXNHR_3$ where X is O or S and R_3 is C_{1-4} alkyl, C_{2-4} alkenyl, phenyl or phenyl C_{1-4} alkyl, any phenyl moiety being optionally substituted; and R_4 is hydrogen or C_{1-4} alkyl.

3. A compound according to claim 1 of formula (IV):



(IV)

wherein
R_1^2 is
a group COR_2 where R_2 is C_{2-3} alkoxy, phenyl C_{1-} alkoxy, the phenyl moiety being optionally substituted, or C_{1-4} alkoxy C_{3-4} alkoxy; or a group $CXNHR_3$ where X is O or S and R_3 is C_{2-4} alkyl, C_{2-4} alkenyl, phenyl or phenyl C_{1-4} alkyl, any phenyl moiety being optionally substituted; and the remaining variables are as defined in claim 1.

4. A compound according to claim 1 of formula (VI):



(VI)

wherein:
n and R_1 are as defined in claim 1; and R_6 is hydrogen, C_{1-4} alkyl, C_{1-4} alkoxy, C_{2-7} acyloxy, cyano or trifluoromethyl.

5. A compound according to claim 4, of formula (VII):



(VII)

wherein

n is 2, 3 or 4; and
$R_1{}^3$ is C_{3-8} alkanoyl, C_{2-3} alkoxycarbonyl, or $CXNHR^1{}_3$ where X is O or S, and $R^1{}_3$ is C_{3-4} alkyl.

6. A compound according to claim 5, of formula (VIII):



(VIII)

wherein R^1_3 is as defined in claim 5, and n^1 is 2 or 3.

7. A compound accorrding to claim 1 which is

4-(5-phenoxy-4-hydroxypentylamino)-1-propylamino-carbonylpiperidine

4-(5-phenoxy-4-hydroxypentylamino)-1-propylaminothio-carbonylpiperidine

4-(5-phenoxy-4-hydroxybutylamino)-1-propylamino-carbonylpiperidine

4-(5-phenoxy-4-hydroxyhexylamino)-1-propylamino-carbonylpiperidine, or

4-(5-phenoxy-4-hydroxypentylamino)-1-butylamino-carbonylpiperidine, or a pharmaceutically acceptable salt thereof.

8. A process for the preparation of a compound according to claim 1 which process comprises the reaction of the compounds of the formulae (IX) and (X):

(IX)

(X)

wherein

R_9 is R_1 as defined or benzyl optionally substituted in the phenyl ring;

i) a) L is CHR_5JNH_2 and X and Y together are oxo;

b) L is $CH_2R_5J^1CHO$ or $CH_2R_5J^2COCH_3$ where J^1 is C_{2-4} polymethylene optionally substituted by one or two groups selected from methyl or optionally derivatised or protected hydroxy, and J^2 is C_{2-4} polymethylene optionally substituted by a methyl or optionally derivatised or protected hydroxy group, X is NH_2 and Y is H;

ii) a) L is $CHR_5\ J^3\ Q_1$ or $CHR_5J^1COQ_2$ where J^3 is J with any hydroxy group protected and Q_1 and Q_2 each are a group readily displaceable by a nucleophile, X is NHR_4 and Y is H;

b) L is $CHR_5J^3NHR_4$, X is Q_1 and Y is H; or

c) E is O or S, L is H or an alkali metal atom, X is $Q_2CHR_5-J^2-NR_4$ where Q_3 is a group readily displaceable by a nucelophile and Y is H;

iii) a) L is CHR_5J^4CHO or $CHR_5J^5COCH_3$ where J^4 is a bond or C_{1-2} polymethylene optionally substituted by a methyl or protected or derivatised hydroxy group and J^5 is a bond or C_{1-2} polymethylene, Y is H and X^1 is $M_1J^6NR_{12}$ where J^6 is C_{1-3} polymethylene determined by J^4 or J^5 and optionally substituted by a methyl or derivatised hydroxy group when J^4 is unsubstituted, M_1 is a lithium (I) or halomagnesium (II) group and R_{12} is an N-protecting group; or

b) L is $CHR_5J^4M_1$ or $CHR_5J^5CHM^1.CH_3$, Y is H and X is $CHO.J^6NR_{12}$;

iv) a) L is $CHR_5.J^6$  wherein J^6 is C_{1-3} polymethylene optionally substituted by a methyl or protected or derivatised hydroxy group, Y is H and X is NHR_4;

or

b) E is O or S, L is H or an alkali metal atom, Y is H and X is  J^6NR_4; or

v) ArEL is  where Z and E are each

independantly O or S and L_1 and L_2 are each H or an alkali metal atom, Y is H and X is $Q_1(CH_2)_mCH.JNR_4$ wherein Q_4 and Q_5 are each
Q_5
independently a group readily displaceable by a nucleophile;

and thereafter as necessary reducing the resulting compound, or in the resulting compound converting R_9 benzyl to R_1, deprotecting any protected hydroxy group, converting R_{12} to hydrogen, optionally converting R_1 or R_4 to other R_1 or R_4 and optionally salifying the resultant compound of formula (I).

9. A pharmaceutical composition comprising a compound according to claim 1, or a pharmaceutically acceptable salt thereof, together with a pharmacuetically acceptable carrier.

10. A compound according to claim 1, for use in the treatment of cardiac arrhythmias.

EP 0097000 (3)
C07D211/58-(C07D213/64A)-
(C07D211/74)-(C07D319/20)-
(C07D405/12+319+211)-
(C07C121/34D2C)-(124BG5G3B2)-
(124BG5G3B3)-

Publication number: **0 097 000**
A3

-8- BASIC DOC.- C07D211/58

(12) **EUROPEAN PATENT APPLICATION**

(21) Application number: 83303168.5

(22) Date of filing: 02.06.83

(51) Int. Cl.³: C 07 D 211/58
C 07 D 405/12, A 61 K 31/445
//C07D213/64, C07D211/74,
C07D319/20, C07C93/14,
C07C121/66

(30) Priority: 10.06.82 GB 8216911
25.06.82 GB 8218407
15.03.83 GB 8307081

(43) Date of publication of application:
28.12.83 Bulletin 83/52

(88) Date of deferred publication of search report: 27.12.84

(84) Designated Contracting States:
BE CH DE FR GB IT LI NL SE

(71) Applicant: Beecham Wuelfing GmbH & Co KG
PO Box 25
D-404 Neuss(DE)

(72) Inventor: Maschler, Harald
Asternstrasse 1D
D-3204 Nordstemmen(DE)

(74) Representative: Stott, Michael John et al,
European Patent Attorney Beecham Pharmaceuticals
Great Burgh Yew Tree Bottom Road
Epsom Surrey KT18 5XQ(GB)

(54) **Amine derivatives.**

(57) Compounds of the formula (I):



(I)

and pharmaceutically acceptable acid addition salts thereof, wherein,

Ar is optionally substituted phenyl or naphthyl, or pyridyl;

E is O, S or a bond;

R_4 is hydrogen, and

J is C_{3-5} polymethylene, optionally substituted by one or two groups selected from methyl or optionally derivatised hydroxy; or

Ar and R_4 togethr form a group



where Ar' is optionally substituted 1, 2-phenylene;

Z is O or CH_2, and

m is 0 or 1, when E is O or S, or 1 when E is a bond;

R_1 is hydrogen, C_{1-4} alkyl or optionally substituted phenyl; C_{3-8} alkanoyl, or phenyl C_{2-8} alkanoyl, any phenyl moietybeing optionally substituted; a group COR_2 where R_2 is C_{2-3} alkoxy, phenyl C_{1-4}alkoxy, the phenyl moiety being optionally substituted, or C_{1-4} alkoxy C_{3-4} alkoxy; or a group $CXNHR_3$ where X is O or S and R_3 is C_{2-4}alkyl, C_{2-4} alkenyl, phenyl or phenyl C_{1-4} alkyl, any phenyl moiety being optionally substituted; and R_4 is hydrogen or C_{1-4} alkyl, compositions containing them, and processes for their preparation.

EP 0 097 000 A3

0097000

Application number

EP 83 30 3168

European Patent Office

EUROPEAN SEARCH REPORT

DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. ³)
A	US-A-3 147 268 (R.I. MELTZER)		C 07 D 211/58 C 07 D 405/12 A 61 K 31/445// C 07 D 213/64 C 07 D 211/74 C 07 D 319/20 C 07 C 93/14 C 07 C 121/66
A	EP-A-0 029 707 (KYOWA HAKKO KOGYO CO., LTD.) * abstract *	1	

TECHNICAL FIELDS SEARCHED (Int. Cl. ³)

C 07 D 211/00
C 07 D 405/00

The present search report has been drawn up for all claims

Place of search	Date of completion of the search	Examiner
THE HAGUE	24-09-1984	MAISONNEUVE J.A.

CATEGORY OF CITED DOCUMENTS

X : particularly relevant if taken alone
Y : particularly relevant if combined with another document of the same category
A : technological background
O : non-written disclosure
P : intermediate document

T : theory or principle underlying the invention
E : earlier patent document, but published on, or after the filing date
D : document cited in the application
L : document cited for other reasons

& : member of the same patent family, corresponding document

EPO Form 1503 03.82